Opinion|Videos|May 5, 2025
From AAD 2025 to the Future: Advancements in Dermatology to Watch
A panelist discusses how the evolving landscape of atopic dermatitis treatment is moving toward a more personalized approach that carefully balances efficacy goals with safety considerations, incorporating new targeted therapies alongside traditional options while also expressing excitement about emerging research in dermatology including novel bispecific antibodies, microbiome-based interventions, and noninvasive diagnostic technologies that may revolutionize disease management in the coming years.
Advertisement
Episodes in this series
- How do you envision the treatment of atopic dermatitis evolving, particularly regarding the balance between efficacy, safety, and patient management?
- Please discuss any other data in the scope of dermatology released at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) that you find noteworthy to share with colleagues.
- Outside of AAD 2025, what ongoing research efforts are you most excited for in the treatment and management of dermatologic conditions? What can we look forward to through the end of the year and beyond?
Advertisement
Related to this article
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5